Olympiad Research LP Boosts Holdings in Catalent, Inc. (NYSE:CTLT)

Olympiad Research LP boosted its stake in Catalent, Inc. (NYSE:CTLT - Free Report) by 93.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,009 shares of the company's stock after acquiring an additional 15,924 shares during the period. Catalent accounts for 1.3% of Olympiad Research LP's investment portfolio, making the stock its 13th largest holding. Olympiad Research LP's holdings in Catalent were worth $1,999,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in CTLT. Mirae Asset Global Investments Co. Ltd. increased its holdings in Catalent by 33.8% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,789 shares of the company's stock worth $1,230,000 after purchasing an additional 5,499 shares in the last quarter. BNP Paribas Financial Markets increased its stake in shares of Catalent by 154.6% in the 1st quarter. BNP Paribas Financial Markets now owns 216,311 shares of the company's stock valued at $12,211,000 after acquiring an additional 131,360 shares in the last quarter. Nordea Investment Management AB increased its stake in shares of Catalent by 10.2% in the 1st quarter. Nordea Investment Management AB now owns 11,874 shares of the company's stock valued at $672,000 after acquiring an additional 1,096 shares in the last quarter. Daiwa Securities Group Inc. lifted its position in shares of Catalent by 8.3% during the 1st quarter. Daiwa Securities Group Inc. now owns 26,397 shares of the company's stock valued at $1,490,000 after acquiring an additional 2,017 shares during the period. Finally, Quantbot Technologies LP bought a new position in Catalent during the first quarter worth $625,000.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. StockNews.com downgraded shares of Catalent from a "hold" rating to a "sell" rating in a research note on Wednesday. Baird R W lowered Catalent from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 24th. William Blair reissued a "market perform" rating on shares of Catalent in a research note on Tuesday, September 3rd. Robert W. Baird reaffirmed a "neutral" rating and set a $63.50 target price on shares of Catalent in a research report on Tuesday, September 24th. Finally, Royal Bank of Canada reissued a "sector perform" rating and issued a $63.50 price target on shares of Catalent in a research report on Thursday, July 11th. One investment analyst has rated the stock with a sell rating and eight have assigned a hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $59.83.

Catalent Trading Down 0.1 %

Shares of CTLT stock traded down $0.03 during trading hours on Thursday, reaching $59.92. The company had a trading volume of 2,129,566 shares, compared to its average volume of 2,049,562. The company has a quick ratio of 1.96, a current ratio of 2.52 and a debt-to-equity ratio of 1.35. Catalent, Inc. has a 12 month low of $32.38 and a 12 month high of $61.20. The business has a fifty day simple moving average of $60.03 and a 200-day simple moving average of $58.03.

Catalent (NYSE:CTLT - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.06 billion. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. Catalent's revenue was up 4.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.10) earnings per share. Analysts anticipate that Catalent, Inc. will post 0.95 EPS for the current fiscal year.

Insider Activity at Catalent

In other Catalent news, insider David Mcerlane sold 1,994 shares of the company's stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the sale, the insider now directly owns 36,304 shares of the company's stock, valued at approximately $2,177,150.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.31% of the stock is owned by insiders.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.